RG7314
From Infogalactic: the planetary knowledge core
RG7314 is a selective small molecule antagonist of the vasopressin V1A receptor which is under development by Roche for the treatment of autism.[1] As of August 2014, it is in phase II clinical trials for this indication.[2]
See also
References
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ A Study of RG7314 to Investigate Efficacy and Safety in Individuals With Autism Spectrum Disorders, at ClinicalTrials.gov; retrieved September 2, 2014
External links
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
Categories:
- Articles which use infobox templates with no data rows
- Infobox drug articles without a structure image
- Chemical articles without CAS Registry Number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugboxes with an unspecified ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Hormonal agents
- Vasopressin receptor antagonists
- Nervous system drug stubs
